SGPNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
SpyGlass Pharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$24.60+0.60 (+2.50%)
Close on Oct 19, 2026
- Market cap
- $822.61M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | After market close | – | $-0.59 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | After market close | – | $-0.69 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 26, 2026 | After market close | – | $-5.72 | – |
Press releases
Announcements SpyGlass Pharma filed with the SEC
SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System
Other events · EX-99.1 to Form 8-K
SpyGlass Pharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K